收费全文 | 7908篇 |
免费 | 718篇 |
国内免费 | 13篇 |
耳鼻咽喉 | 371篇 |
儿科学 | 511篇 |
妇产科学 | 372篇 |
基础医学 | 514篇 |
口腔科学 | 511篇 |
临床医学 | 713篇 |
内科学 | 1616篇 |
皮肤病学 | 202篇 |
神经病学 | 647篇 |
特种医学 | 265篇 |
外科学 | 1782篇 |
综合类 | 60篇 |
一般理论 | 1篇 |
预防医学 | 250篇 |
眼科学 | 252篇 |
药学 | 349篇 |
中国医学 | 25篇 |
肿瘤学 | 198篇 |
2024年 | 22篇 |
2023年 | 208篇 |
2022年 | 136篇 |
2021年 | 319篇 |
2020年 | 223篇 |
2019年 | 283篇 |
2018年 | 591篇 |
2017年 | 461篇 |
2016年 | 592篇 |
2015年 | 430篇 |
2014年 | 673篇 |
2013年 | 870篇 |
2012年 | 740篇 |
2011年 | 774篇 |
2010年 | 593篇 |
2009年 | 301篇 |
2008年 | 273篇 |
2007年 | 230篇 |
2006年 | 206篇 |
2005年 | 161篇 |
2004年 | 68篇 |
2003年 | 80篇 |
2002年 | 71篇 |
2001年 | 89篇 |
2000年 | 64篇 |
1999年 | 44篇 |
1998年 | 37篇 |
1997年 | 15篇 |
1996年 | 6篇 |
1995年 | 5篇 |
1994年 | 8篇 |
1993年 | 2篇 |
1992年 | 6篇 |
1991年 | 8篇 |
1990年 | 14篇 |
1989年 | 7篇 |
1988年 | 5篇 |
1987年 | 6篇 |
1986年 | 4篇 |
1984年 | 1篇 |
1983年 | 1篇 |
1979年 | 1篇 |
1978年 | 3篇 |
1975年 | 1篇 |
1973年 | 3篇 |
1972年 | 1篇 |
1971年 | 1篇 |
1969年 | 1篇 |
1928年 | 1篇 |
Background
Refractory acute myeloid leukemia (AML) includes AML includes failure of disease to respond to standard induction chemotherapy, relapse within 6 months after first CR, and 2 or more relapses. The outcome of these patients is usually very poor; only a small proportion can be rescued by allogenic hematopoietic stem-cell transplantation (allo-HSCT). The aim of this study was to evaluate the efficacy and feasibility of allo-HSCT in patients with refractory AML.Patients and Methods
We retrospectively analyzed the clinical outcome of 91 patients who were diagnosed with treatment-refractory AML at Hacettepe University Hospital between January 2002 and June 2018. Patients' disease status included refractory AML, defined as failure to respond to standard induction chemotherapy and relapse within 6 months after first complete remission.Results
The median follow-up was 12 months (range, 0.5-184 months) for the entire group. Kaplan-Meier estimates of the 3-year overall survival for patients who underwent allo-HSCT and patients who received only salvage chemotherapy were 67% and 12%, respectively. Additionally, the Kaplan-Meier estimates of 5-year overall survival for patients who underwent allo-HSCT and patients who received only salvage chemotherapy were 44% and 4%, respectively (P < .001). Complete remission was obtained in 25 patients (83.3%) who underwent allo-HSCT; however, the disease of only 3 patients (3.8%) exhibited complete response after salvage chemotherapy.Conclusion
Allo-HSCT is still the best-known treatment option with curative potential in patients with treatment-refractory AML. Therefore, all efforts should be made in an attempt to find a suitable matched donor in order to perform allo-HSCT. 相似文献Butyrylcholinesterase (BChE) is a serine esterase that plays a role in the detoxification of natural as well as synthetic ester-bond-containing compounds. Alterations in BChE activity are associated with a number of diseases. Cholinergic system abnormalities in particular are correlated with the formation of senile plaques in Alzheimer’s disease (AD), and administration of cholinesterase inhibitors is a common therapeutic approach used to treat AD.
Here, our aim was to study the interaction between BChE and fluoxetine.
Molecular docking simulations revealed that fluoxetine penetrated deep into the active-site gorge of BChE and that it was engaged in stabilizing noncovalent interactions with multiple subsites. In substrate kinetic studies, the Vm, Km, kcat and kcat/Km values were found to be 20.59?±?0.36?U mg?1 protein, 194?±?14?µM, 1.3?×?108?s?1 and 6.7?×?105?µM?1s?1, respectively. Based on inhibitory studies, fluoxetine appeared to inhibit BChE competitively, with an IC50 value of 104?µM and a Ki value of 36.3?±?4.7?µM.
Overall, both the low Ki value and the high number of BChE–fluoxetine interactions suggest that fluoxetine is a potent inhibitor of BChE, although in vivo mechanisms for the direct effects of BChE inhibition on various pathologies remain to be further investigated.